Amneal Pharmaceuticals, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending March 31, 2025: -6.90%

Amneal Pharmaceuticals, Inc. Return on Equity (ROE) is -6.90% for the Trailing 12 Months (TTM) ending March 31, 2025, a -93.81% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.
  • Amneal Pharmaceuticals, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending March 31, 2024 was -111.52%, a 79.61% change year over year.
  • Amneal Pharmaceuticals, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending March 31, 2023 was -62.09%, a 8,982.48% change year over year.
  • Amneal Pharmaceuticals, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending March 31, 2022 was -0.68%, a -87.41% change year over year.
  • Amneal Pharmaceuticals, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending March 31, 2021 was -5.43%, a -89.63% change year over year.
Key Data
Date Return on Equity (ROE) Return on Assets (ROA) Revenue Per Share Free Cash Flow Per Share